BioLineRx (BLRX) Net Income towards Common Stockholders (2013 - 2025)
BioLineRx (BLRX) posted Net Income towards Common Stockholders of -$2.8 million for Q4 2025, down 83.68% on a QoQ basis from -$1.5 million in Q3 2025, and down 816.88% year-over-year from $391000.0 in Q4 2024.
BioLineRx (BLRX) has 13 years of Net Income towards Common Stockholders data on file, last reported at -$2.8 million in Q4 2025.
- In Q4 2025, Net Income towards Common Stockholders fell 816.88% year-over-year to -$2.8 million; the TTM figure through Dec 2025 stood at -$7.5 million (up 19.91% YoY), while the FY2025 annual figure was -$7.5 million, up 19.91% from the prior year.
- Net Income towards Common Stockholders slipped to -$2.8 million in Q4 2025, from -$1.5 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at $391000.0 in Q4 2024 and bottomed at -$18.7 million in Q4 2023.
- A 5-year average of -$5.5 million and a median of -$5.8 million in 2022 frame the typical range for Net Income towards Common Stockholders.
- Annual changes were most pronounced in 2024 — Net Income towards Common Stockholders surged 102.09% — and 2025, when it plunged 816.88%.
- Year by year, Net Income towards Common Stockholders stood at -$6.1 million in 2021, then climbed by 7.11% to -$5.7 million in 2022, then plunged by 228.52% to -$18.7 million in 2023, then surged by 102.09% to $391000.0 in 2024, then plunged by 816.88% to -$2.8 million in 2025.
- The last three Net Income towards Common Stockholders figures came in at -$2.8 million (Q4 2025), -$1.5 million (Q3 2025), and -$1.5 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -13.56 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 2.50 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -3.63 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 205.99 Mn |
| 10 | BioLineRx | 9.32 Bn | 9.30 Bn | 154,000.00 | -2.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -2.80 Mn |
| Sep 30, 2025 | -1.53 Mn |
| Jun 30, 2025 | -1.54 Mn |
| Mar 31, 2025 | -1.68 Mn |
| Dec 31, 2024 | 391,000.00 |
| Sep 30, 2024 | -3.33 Mn |
| Jun 30, 2024 | -3.15 Mn |
| Mar 31, 2024 | -3.33 Mn |
| Dec 31, 2023 | -13.45 Mn |
| Sep 30, 2023 | -11.21 Mn |
| Jun 30, 2023 | -8.14 Mn |
| Mar 31, 2023 | -8.95 Mn |
| Dec 31, 2022 | -6.63 Mn |
| Sep 30, 2022 | -6.70 Mn |
| Jun 30, 2022 | -7.14 Mn |
| Mar 31, 2022 | -5.83 Mn |
| Dec 31, 2021 | -6.13 Mn |
| Sep 30, 2021 | -5.90 Mn |
| Jun 30, 2021 | -6.14 Mn |
| Mar 31, 2021 | -5.03 Mn |
| Dec 31, 2020 | -5.33 Mn |
| Sep 30, 2020 | -4.31 Mn |
| Jun 30, 2020 | -5.14 Mn |
| Mar 31, 2020 | -6.29 Mn |
| Dec 31, 2019 | -8.47 Mn |
| Sep 30, 2019 | -5.80 Mn |
| Jun 30, 2019 | -5.87 Mn |
| Mar 31, 2019 | -4.92 Mn |
| Dec 31, 2018 | -6.53 Mn |
| Sep 30, 2018 | -6.05 Mn |
| Jun 30, 2018 | -5.43 Mn |
| Mar 31, 2018 | -6.25 Mn |
| Dec 31, 2017 | -7.43 Mn |
| Sep 30, 2017 | -6.90 Mn |
| Jun 30, 2017 | -4.89 Mn |
| Mar 31, 2017 | -4.84 Mn |
| Dec 31, 2016 | -4.30 Mn |
| Sep 30, 2016 | -4.31 Mn |
| Jun 30, 2016 | -3.77 Mn |
| Mar 31, 2016 | -3.63 Mn |
| Dec 31, 2015 | -4.01 Mn |
| Sep 30, 2015 | -3.43 Mn |
| Jun 30, 2015 | -3.96 Mn |
| Mar 31, 2015 | -4.24 Mn |
| Dec 31, 2014 | -3.79 Mn |
| Sep 30, 2014 | -1.78 Mn |
| Jun 30, 2014 | -3.44 Mn |
| Mar 31, 2014 | -3.64 Mn |
| Dec 31, 2013 | -1.98 Mn |
| Sep 30, 2013 | -2.58 Mn |
| Jun 30, 2013 | -3.79 Mn |
| Mar 31, 2013 | -5.77 Mn |